CLL Society and several chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL / SLL) patients participated in a Centers for Medicare & Medicaid Services (CMS) Roundtable on Calquence (acalabrutinib) on April 17, 2025. This was followed by a CMS Town Hall on April 30, where three members of the CLL Society’s Medical Advisory Board presented.
Both events were part of an ongoing effort to educate CMS about CLL, the significance of acalabrutinib, and the therapeutic alternatives available to patients.
CMS’s questions during these events revealed a limited understanding of the cancer treatment paradigm, particularly the management of CLL / SLL as a chronic condition.
View slides below highlighting key points shared by our community.
